Why Sage Therapeutics Jumped Today

What happened After releasing encouraging data from Part A of a Phase 2 trial shares of SAGE Therapeutics NASDAQ SAGE a 160 clinical stage biotech focused on diseases of the central nervous system rose by 14 as of 3 20 p m EST on Monday So what